Collectively, these findings indicate that co-expression of PHLDA1/2 exerts a synergistic effect on the inhibition of AKT activity, and that oncogene-induced hyperactivation of ERK signaling represses AKT activation in human cancer mainly through the simultaneous induction of PHLDA1/2. Here, PHLDA1 is linked to cancer.